Statement of Organization, Functions and Delegations of Authority, 16292-16293 [05-6205]
Download as PDF
<![CDATA[
16292
Federal Register / Vol. 70, No. 60 / Wednesday, March 30, 2005 / Notices
for health claims on food labels that do
not meet a standard of significant
scientific agreement (SSA). These
claims, referred to as ‘‘qualified health
claims,’’ are assigned a specific level of
scientific support according to an
interim evidence-based ranking system
for scientific data. The report also
identified the need for consumer
research to examine ways to
communicate the level of scientific
support associated with health claims
that do not meet the traditional SSA
standard. In the fall of 2004, FDA issued
letters of enforcement discretion for two
qualified health claims. The claims
relate to the reduction of risk of
coronary heart disease from the
consumption of monounsaturated fatty
acids from olive oil and omega-3 fatty
acids. The qualified health claims
appear below:
1. Limited and not conclusive
scientific evidence suggests that eating
about 2 tablespoons (23 grams) of olive
oil daily may reduce the risk of coronary
heart disease due to the
monounsaturated fat in olive oil. To
achieve this possible benefit, olive oil is
to replace a similar amount of saturated
fat and not increase the total number of
calories you eat in a day. One serving
of this product [Name of food] contains
[x] grams of olive oil.
2. Supportive but not conclusive
research shows that consumption of
EPA and DHA omega-3 fatty acids may
reduce the risk of coronary heart
disease. One serving of [name of food]
provides [x] grams of EPA and DHA
omega-3 fatty acids. [See nutrition
information for total fat, saturated fat
and cholesterol content.]
The study proposed here is part of an
ongoing effort by FDA to collect data
concerning qualified health claims and
their impact on consumer perceptions
and behavior. Previous FDA studies
have examined hypothetical qualified
health claims to evaluate ways to
communicate the strength of scientific
evidence supporting a claim. This study
will examine two issued health claims
to evaluate whether consumers
comprehend the information contained
within the claim and whether
consumers understand the relative
significance of the information in the
context of a total diet. In addition, the
study will broaden FDA’s
understanding about how consumers
interpret qualified health claims,
particularly as they pertain to the level
of scientific evidence conveyed by the
message and to any differences there
may be between qualified health claims
on dietary supplements versus foods.
The experimental study data will be
collected using participants of an
Internet panel of approximately 600,000
people. Participation in the
experimental study is voluntary.
FDA estimates the burden of this
collection of information as follows:
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
Annual Frequency per
Response
No. of Respondents
30 (Pre-test)
1,600 (Experiment)
Total
1There
Total Annual
Responses
1
1
Hours per Response
30
1,600
Total Hours
.167
.167
5
267
272
are no capital costs or operating and maintenance costs associated with this collection of information.
FDA’s burden estimate is based on
prior experience with internet panel
experiments similar to the study
proposed here.
Minority Health to the Office of
Minority Health and Health Disparities,
and revises the functional statement as
follows:
Dated: March 21, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–6203 Filed 3–29–05; 8:45 am]
Office of Minority Health and Health
Disparities (RA9)
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Statement of Organization, Functions
and Delegations of Authority
This notice amends Part R of the
Statement of Organization, Functions
and Delegations of Authority of the
Department of Health and Human
Services (DHHS), Health Resources and
Services Administration (HRSA) (61 FR
65062–65065, December 10, 1996 and as
last amended at 62 FR 27614–27615,
dated May 20, 1997).
This notice is to amend the functions
of a component of the Office of the
Administrator. Specifically, this notice
changes the name of the Office of
VerDate jul<14>2003
15:07 Mar 29, 2005
Jkt 205001
Serves as the principal advisor and
coordinator to the agency for the special
needs of minority and disadvantaged
populations including: (1) Providing
leadership and direction to address HHS
and HRSA Strategic Plan goals and
objectives related to improving minority
health and eliminating health
disparities; (2) establishing and
managing an agency-wide data
collection system for minority health
activities and initiatives including the
White House Initiatives for Historically
Black Colleges and Universities,
Educational Excellence for Hispanic
Americans, Tribal Colleges and
Universities, Asian Americans and
Pacific Islanders, and Departmental
Initiatives; (3) implementing activities
to increase the availability of data to
monitor the impact of agency programs
in improving minority health and
eliminating health disparities; (4)
participating in the formulation of
HRSA’s goals, policies, legislative
PO 00000
Frm 00083
Fmt 4703
Sfmt 4703
proposals, priorities, and strategies as
they affect health professional
organizations and institutions of higher
education and others involved in or
concerned with the delivery of
culturally-appropriate, quality health
services to minorities and
disadvantaged populations; (5)
consulting with Federal agencies and
other public and private sector agencies
and organizations to collaborate in
addressing minority health and health
disparities issues, including enhancing
cultural competence in health service
providers; (6) establishing short-term
and long-range objectives; and (7)
participating in the focus of activities
and objectives in assuring equity in
access to resources and health careers
for minorities and the disadvantaged.
Section RA–30
Authority
Delegation of
All delegations of authority which
were in effect immediately prior to the
effective date hereof have been
continued in effect in them or their
successors pending further redelegation.
I hereby ratify and affirm all actions
taken by any DHHS official which
involved the exercise of these
E:\FR\FM\30MRN1.SGM
30MRN1
Federal Register / Vol. 70, No. 60 / Wednesday, March 30, 2005 / Notices
16293
authorities prior to the effective date of
this delegation.
This reorganization is effective upon
the date of signature.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
Dated: March 21, 2005.
Elizabeth M. Duke,
Administrator.
[FR Doc. 05–6205 Filed 3–29–05; 8:45 am]
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Complementary
and Alternative Medicine; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Complementary and Alternative Medicine
Special Emphasis Panel, Loan Repayment
Program Review.
Date: April 13, 2005.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Laurie Friedman Donze,
PhD, Scientific Review Administrator,
National Center for Complementary and
Alternative Medicine, National Institutes of
Health, 6707 Democracy Blvd., Suite 401,
Bethesda, MD 20892, 301–402–1030,
donzel@mail.nih.gov.
Dated: March 22, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–6216 Filed 3–29–05; 8:45 am]
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel,
Patient-Oriented Career Training Grant
Review.
Date: April 5, 2005.
Time: 2 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone conference call.)
Contact Person: Roy L. White, PHD, 6701
Rockledge Drive, Room 7202, MSC 7924,
Division of Extramural Affairs; Review
Branch, National Heart, Lung, and Blood
Institute, National Institutes of Health,
Bethesda, MD 20892. 301–435–0310.
whiterl@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: March 22, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–6219 Filed 3–29–05; 8:45 am]
BILLING CODE 4140–01–M
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel, Loan Repayment Program.
Date: April 27, 2005.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Adriana Costero, PhD,
Scientific Review Administrator, Scientific
Review Program, National Institute of Allergy
and Infectious Diseases/NIH/DHHS, 6700B
Rockledge Drive, MSC–7616, Bethesda, MD
20892, (301) 451–4573,
acostero@niaid.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel, Loan Repayment Program.
Date: April 28, 2005.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Adriana Costero, PhD,
Scientific Review Administrator, Scientific
Review Program, National Institute of Allergy
and Infectious Diseases/NIH/DHHS, 6700B
Rockledge Drive, MSC–7616, Bethesda, MD
20892, (301) 451–4573,
acostero@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
LaVerne Y. Stringfield,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–6210 Filed 3–29–05; 8:45 am]
BILLING CODE 4140–01–M
BILLING CODE 4140–01–M
VerDate jul<14>2003
15:07 Mar 29, 2005
Jkt 205001
PO 00000
Frm 00084
Fmt 4703
Sfmt 4703
E:\FR\FM\30MRN1.SGM
30MRN1
]]>Agencies
[Federal Register Volume 70, Number 60 (Wednesday, March 30, 2005)]
[Notices]
[Pages 16292-16293]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-6205]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Statement of Organization, Functions and Delegations of Authority
This notice amends Part R of the Statement of Organization,
Functions and Delegations of Authority of the Department of Health and
Human Services (DHHS), Health Resources and Services Administration
(HRSA) (61 FR 65062-65065, December 10, 1996 and as last amended at 62
FR 27614-27615, dated May 20, 1997).
This notice is to amend the functions of a component of the Office
of the Administrator. Specifically, this notice changes the name of the
Office of Minority Health to the Office of Minority Health and Health
Disparities, and revises the functional statement as follows:
Office of Minority Health and Health Disparities (RA9)
Serves as the principal advisor and coordinator to the agency for
the special needs of minority and disadvantaged populations including:
(1) Providing leadership and direction to address HHS and HRSA
Strategic Plan goals and objectives related to improving minority
health and eliminating health disparities; (2) establishing and
managing an agency-wide data collection system for minority health
activities and initiatives including the White House Initiatives for
Historically Black Colleges and Universities, Educational Excellence
for Hispanic Americans, Tribal Colleges and Universities, Asian
Americans and Pacific Islanders, and Departmental Initiatives; (3)
implementing activities to increase the availability of data to monitor
the impact of agency programs in improving minority health and
eliminating health disparities; (4) participating in the formulation of
HRSA's goals, policies, legislative proposals, priorities, and
strategies as they affect health professional organizations and
institutions of higher education and others involved in or concerned
with the delivery of culturally-appropriate, quality health services to
minorities and disadvantaged populations; (5) consulting with Federal
agencies and other public and private sector agencies and organizations
to collaborate in addressing minority health and health disparities
issues, including enhancing cultural competence in health service
providers; (6) establishing short-term and long-range objectives; and
(7) participating in the focus of activities and objectives in assuring
equity in access to resources and health careers for minorities and the
disadvantaged.
Section RA-30 Delegation of Authority
All delegations of authority which were in effect immediately prior
to the effective date hereof have been continued in effect in them or
their successors pending further redelegation. I hereby ratify and
affirm all actions taken by any DHHS official which involved the
exercise of these
[[Page 16293]]
authorities prior to the effective date of this delegation.
This reorganization is effective upon the date of signature.
Dated: March 21, 2005.
Elizabeth M. Duke,
Administrator.
[FR Doc. 05-6205 Filed 3-29-05; 8:45 am]
BILLING CODE 4165-15-P
